Spectral AI, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MDAI research report →
Range $4 – $4
Price Chart
About the company
Spectral AI, Inc. , an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation; and delivers a binary prediction on the wounds capacity to heal or not heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed decision regarding the treatment of the patient’s wounds.
- CEO
- Vincent S. Capone
- IPO
- 2021
- Employees
- 65
- HQ
- Dallas, TX, US
Get TickerSpark's AI analysis on MDAI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $33.47M
- P/E
- -3.98
- PEG
- 0.07
- P/S
- 2.96
- P/B
- -2.73
- EV/EBITDA
- -5.27
- Div Yield
- 0.00%
- Gross Margin
- 38.32%
- Op Margin
- -89.61%
- Net Margin
- -74.56%
- ROE
- 100.93%
- ROIC
- -1066.28%
Latest fiscal year · YoY change
- Revenue
- $19.65M-33.6%
- Gross Profit
- $8.93M-32.8%
- Op Income
- $-8,603,000
- Net Income
- $-7,571,000+50.6%
- EPS
- $-0.29+65.9%
- OCF Growth
- -7.8%
- FCF Growth
- -7.8%
- 52W High
- $2.97
- 52W Low
- $1.00
- 50D MA
- $1.53
- 200D MA
- $1.68
- Beta
- 1.25
- RSI (14)
- 24
- Avg Volume
- 142.00K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Spectral AI said Q3 reflected a continued shift toward commercialization, but revenue and gross margin fell under a new BARDA cost-share structure while the company reiterated a goal of first commercial sales in 2026.· November 10, 2026
- Q3 R&D revenue was $2.9 million, down 24.7% from $3.8 million a year ago, as BARDA revenue fell to $2.7 million from $3.4 million and other U.S. government revenue dropped to $100,000 from $400,000.
- Gross margin compressed to 27.2% from 42.7% because BARDA cost-share expenses were recorded in cost of revenue.
- Net loss was $3.7 million, or $0.11 per share, versus $3.6 million, or $0.13 per share, last year.
- Management still sees first commercial sales in 2026 and said it began manufacturing the first 30 DeepView AI systems for BARDA-supported deployments.
- The company lowered 2026 R&D revenue guidance to approximately $13 million from approximately $18.5 million, citing the completed MTEC program and timing shifts in BARDA work.
Q3 2026 R&D revenue was $2.9 million, down 24.7% from $3.8 million in Q3 2025. BARDA revenue was $2.7 million versus $3.4 million a year ago, and other U.S. government program revenue was $100,000 versus $400,000. Gross margin was 27.2% compared with 42.7%. Total operating expenses declined 4% to $4.7 million from $5.0 million. Net loss was $3.7 million, or $0.11 per basic and diluted share, versus $3.6 million, or $0.13 per share, in Q3 2025. Cash was $11.2 million at 9/30/2026 versus $15.4 million at 12/31/2025. Management updated 2026 R&D revenue guidance to approximately $13 million from approximately $18.5 million, excluding revenue from DeepView AI device sales and any new or extended government awards. The company said it expects first commercial sales in 2026 and expects the NTAP determination in August 2027, with UKCA approval now expected in early 2027.
Vincent Capone framed the quarter as evidence that Spectral AI is moving from a research organization to a commercial business. He emphasized commercialization milestones: manufacturing the first 30 DeepView AI systems, advancing U.S. and U.K. studies, pursuing reimbursement, and building a national sales footprint through burn-center relationships. His tone was optimistic but measured, repeatedly stressing that adoption will require clinical confidence, workflow integration, and consistent execution.
David McGuire explained that Q3 was the first full quarter under BARDA’s follow-on development phase, where BARDA reimburses only part of development costs and the company funds the rest. He highlighted the key figures: R&D revenue of $2.9 million, gross margin of 27.2%, operating expenses of $4.7 million, net loss of $3.7 million, and cash of $11.2 million. He also noted the Avenue facility is fully drawn at $15 million, with interest-only payments through March 2027 and maturity in March 2028, and said commercial sales should carry higher margins than development work.
Analysts focused on NTAP reimbursement, pricing, adoption hurdles, and go-to-market strategy. Management said the NTAP application targets hospitals rather than physicians, requested a reimbursement code of $2,750 per patient, and expects a decision in August 2027 with a 2- to 3-year term beginning in October 2027. On commercialization, management said procurement at burn centers is the main hurdle, that it is pursuing both purchase and lease models over minimum three-year terms, and that adoption is being driven by key opinion leaders and on-site demonstrations rather than distributor partnerships.
The call showed a company moving closer to actual commercial deployment, with first commercial sales still targeted for 2026 and manufacturing underway for the first 30 systems. Management also pointed to multiple potential tailwinds: NTAP reimbursement, a planned TNT study to support CPT 1 coding, U.K. label expansion, and a business model that could generate recurring software and service revenue.
Near-term financials are under pressure from the BARDA cost-share structure, which cut reported revenue growth and gross margin, and management reduced 2026 R&D revenue guidance to approximately $13 million. Commercial adoption is still early, with procurement at burn centers described as the main hurdle, while UKCA approval slipped from year-end to early 2027 and the NTAP decision is not expected until August 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 71.5%
- Shares Outstanding
- 32.18M
- Float Shares
- 23.00M
of shares held by institutions
35 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 980.67K | ▼ 13.74K |
| Highlander Partners, L.P. | 900.00K | 0 |
| Vanguard Group Inc | 842.05K | ▲ 228.78K |
| Marshall Wace, Llp | 646.11K | ▼ 181.34K |
| Bridgeway Capital Management, LLC | 287.00K | ▲ 88.00K |
| Geode Capital Management, LLC | 230.40K | ▲ 7.80K |
| Vanguard Fiduciary Trust Co | 173.72K | ▲ 31.06K |
| Ubs Group AG | 167.26K | ▼ 58.56K |
| Lpl Financial LLC | 163.80K | ▲ 3.10K |
| Blackrock, Inc. | 157.54K | ▼ 4.24K |
| State Street Corp | 88.50K | ▲ 12.90K |
| Rathbones Group PLC | 87.05K | 0 |
Held by 22 ETFs
Biggest fund positions in MDAI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | Mellish Martin C.B. | other | 0 |
| Nov 13, 26 | DiMaio John Michael | other | 0 |
| Nov 13, 26 | Cotton Richard John | other | 0 |
| Sep 28, 26 | DiMaio John Michael | other | 32,000 |
| Sep 23, 26 | DiMaio John Michael | other | 60,000 |
| Sep 21, 26 | DiMaio John Michael | other | 21,012 |
| Sep 18, 26 | DiMaio John Michael | other | 10,988 |
| Sep 11, 26 | DiMaio John Michael | other | 22,000 |
| Sep 10, 26 | DiMaio John Michael | other | 10,000 |
| Aug 13, 26 | DiMaio John Michael | other | 35,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MDAI coverage
Recent articles, reports, and earnings notes.
No research on MDAI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MDAI report →Spectral AI: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 21
Spectral AI, Inc. (MDAI) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
Spectral AI Announces 2026 Third Quarter Financial Results
globenewswire.com · Nov 10
Spectral AI Schedules 2026 Third Quarter Financial Results and Conference Call
globenewswire.com · Oct 28
Spectral AI's DeepView™ System Showcased at the 2026 American College of Emergency Physicians (ACEP) Scientific Assembly
globenewswire.com · Oct 13
Spectral AI Submits New Technology Add-On Payment (NTAP) Application for DeepView™ System
globenewswire.com · Oct 6
Spectral AI Announces First Site Initiation Visit for DeepView System™ Clinical Study Supporting Label Expansion Strategy to Burns of the Head, Hands, and Feet
globenewswire.com · Oct 1
Spectral AI Announces Upcoming Presentation at ACS Clinical Congress 2026 Highlighting the Use of Artificial Intelligence and Multi-Spectral Imaging in the Assessment of Burn Wounds
globenewswire.com · Sep 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.